Rayonex Biomedical

What Rayonex Biomedical does

Rayonex Biomedical GmbH is a privately held German medical device company founded in 1982 by engineer Paul Schmidt in Lennestadt, Sauerland, to develop and commercialize bioresonance therapy products based on his proprietary frequency-spectrum approach. The company's core technology uses dipole antenna systems to transmit therapeutic frequencies intended to support the self-regulation of organisms, packaged across two clinical platforms (the high-end Rayocomp PS 1000 polar 4.0 with touchscreen and exclusive Rayoscan ECG-based analysis module, and the compact mobile Rayocomp PS 10), a consumer wearable line (Mini-Rayonex and Mini-Rayonex 5G), the proprietary Rayonex Analysis and Harmonising System (RAH) of frequency-pattern programs, individualized Green-Card consumables, and a patented nutrient line (Rayobase for alkaline minerals, Rayoflora for acidic vitamins/trace elements, and Rayovita for gut flora). All products are developed and manufactured in a single CO2-neutral, robot-supported facility in Lennestadt, certified to DIN EN ISO 13485:2016.

The business is diversified across three primary customer segments: alternative practitioners and healthcare professionals (B2B/clinical), individual consumers (D2C, including via Amazon and home therapy), and veterinary practitioners. Revenue is generated through hardware device sales, accessory and consumable sales (including Green-Cards), dietary supplements, and paid training and certification programs, with no publicly disclosed pricing. Rayonex sells via direct consultation, a global partner network of sales distributors in 46 countries, an affiliated alternative practitioner school, and event-driven education delivered through seminars, webinars, and the periodic Rayonex Feedback magazine.

The company maintains a research partnership with the Fraunhofer Institute, which has reported up to 45% increases in cell activity under bioresonance influence, and lists multiple randomized, prospective, double-blind clinical studies in the German Register of Clinical Studies (BfArM). Rayonex is privately held, has no disclosed venture capital or private equity backing, and remains independently operated from its single German headquarters following Paul Schmidt's death in 1994.

Name

Rayonex Biomedical

Legal name

Rayonex Biomedical GmbH

Website

https://rayonex.de

Company type

Private

Founded year

1982

Operating status

Operating

Headcount range

51–100 employees

Short description

Rayonex Biomedical GmbH is a German medical device company founded in 1982 that develops, manufactures, and globally distributes bioresonance therapy devices (Rayocomp PS 1000, Rayocomp PS 10, Mini-Rayonex), consumables, and supplements for healthcare practitioners, individual consumers, and veterinary users across 46 countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Lennestadt

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Bioresonance Medical Devices: Sale of medical bioresonance devices including Rayocomp PS 1000 polar 4.0, Rayocomp PS 10, and Mini-Rayonex product line. Devices are manufactured in company's own CO2-neutral facility in Germany.
2. Dietary Supplements: Sale of nutritional products following the Rayonex nutrient concept - Rayobase (minerals), Rayoflora (vitamins and trace elements), and Rayovita. Supplements are designed based on Bioresonance principles.
3. Training and Certification Programs: Entry and further training programs for practitioners, with optional certification that practitioners can display to clients. Seminars and webinars provide knowledge transfer.
4. Accessories and Consumables: Sale of accessory products including area detectors, program cards, and related equipment for use with bioresonance devices.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Rayonex Biomedical designs, manufactures, and sells medical bioresonance therapy devices and accessories based on founder Paul Schmidt's frequency spectrum methodology. The portfolio includes two main practitioner devices (Rayocomp PS 1000 polar 4.0 and Rayocomp PS 10), portable personal-use devices (Mini-Rayonex and Mini-Rayonex 5G), complementary dietary supplements (Rayobase, Rayoflora, Rayovita), and accessories such as Green-Card therapy cards and area detectors, all manufactured at the company's CO2-neutral facility in Lennestadt, Germany.

Product overview

Rayonex Biomedical offers a portfolio of bioresonance therapy devices led by two main hardware platforms: the Rayocomp PS 1000 polar 4.0 (high-end stationary unit with touchscreen and Rayoscan® ECG-based analysis module) and the Rayocomp PS 10 (compact mobile device). Personal-use options include the Mini-Rayonex and Mini-Rayonex 5G portable devices. The ecosystem is supported by the Rayonex Analysis and Harmonising System (RAH) containing therapeutic frequency programs, complementary dietary supplements (Rayobase®, Rayoflora®, Rayovita), and accessories including the Green-Card therapy medium and Area Detector. The company also publishes the standard reference book 'Bioresonance according to Paul Schmidt' and the Rayonex feedback Magazine. All products are manufactured in Germany (Lennestadt, Sauerland) and certified to DIN EN ISO 13485:2016.

Differentiator

Problem solved

Functional benefit

Products and services

• Rayocomp PS 1000 polar 4.0 High-end bioresonance therapy device for human and veterinary application, designed for alternative practitioners and healthcare professionals. Includes client management capability, large intuitive touchscreen, and a powerful dipole antenna system.
• Rayocomp PS 10 Mobile bioresonance therapy device for human and veterinary usage by practitioners, featuring an integrated high-performance battery, modular software design, and compact laptop-sized form factor with intuitive operability.
• Mini-Rayonex 5G Portable bioresonance device for personal use designed for continuous wear. Combines original Mini-Rayonex frequencies with 5G frequency capabilities to support vitality, sleep quality, and recovery.
• Mini-Rayonex Portable bioresonance device for home therapy, worn in pocket or placed bedside. Supports wound healing, energy improvement, and general wellness for individual consumers.
• Rayobase Mineral dietary supplement with pH value above 9.3, part of the patented Rayonex Nutrient Concept developed using bioresonance principles to supplement minerals in the alkaline range.
• Rayoflora Vitamin and trace element dietary supplement with pH value below 7, part of the patented Rayonex Nutrient Concept, supplementing vitamins and trace elements in the acidic pH range.
• Rayovita Intestinal flora dietary supplement designed for healthy colonization of gut flora with strengthening effects on the immune system.
• Green-Card Programmed therapy card consumable containing individual frequency patterns for home therapy. Created based on client analysis and inserted into bioresonance devices for personalized treatment delivery.
• Area Detector (Flächendetektor) Detector accessory used in the bioresonance treatment procedure, connected to Rayocomp devices for area-specific scanning and therapy applications.
• Biofield-forming Products Standalone products providing location-specific energetic influences for protection against environmental electromagnetic frequencies such as 5G networks, WLAN, and screen radiation.

Quantifiable outcome

• Clinical study showed 100% of Rayocomp group patients would recommend the treatment, compared to 26.1% in placebo group
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• Fraunhofer InstitutecoreTechnology or Integration · 1 January 2020Conducted efficacy study on device systems from Rayonex Biomedical GmbH. Study confirmed that Bioresonance according to Paul Schmidt and the RAH meet requirements of an effective therapy with a low level of side-effects. Cell biological studies showed 45% increase in cell activity under bioresonance influence.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Market position

Strengths4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/playlist?list=PLdGornjbSbb6p7I-4daaDYQ9qiIsbbPFc
• Facebookfacebook.com/RayonexBiomedical
• LinkedInlinkedin.com/company/rayonex-biomedical-gmbh

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rayonex Biomedical